Evaluating the effect of immune cells on the outcome of patients with mesothelioma

Br J Cancer. 2017 Oct 24;117(9):1341-1348. doi: 10.1038/bjc.2017.269. Epub 2017 Aug 17.

Abstract

Background: We systematically assessed the prognostic and predictive value of infiltrating adaptive and innate immune cells in a large cohort of patients with advanced mesothelioma.

Methods: A tissue microarray from 302 samples was constructed. Markers of adaptive immune response in T-cells (CD8+, FOXP3+, CD4+, CD45RO+, CD3+) and B-cells (CD20+), and of innate immune response; neutrophils (NP57+), natural killer cells (CD56+) and macrophages (CD68+) were evaluated.

Results: We found that in the epithelioid tumours, high CD4+ and CD20+ counts, and low FOXP3+, CD68+ and NP57+ counts linked to better outcome. In the non-epithelioid group low CD8+ and low FOXP3+ counts were beneficial.On multivariate analysis low FOXP3+ remained independently associated with survival in both groups. In the epithelioid group additionally high CD4+, high CD20+, and low NP57+ counts were prognostic.

Conclusions: Our data demonstrate for the first time, in predominately advanced disease, the association of key markers of adaptive and innate immunity with survival and the differential effect of histology. A better understanding of the immunological drivers of the different subtypes of mesothelioma will assist prognostication and disease-specific clinical decision-making.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • B-Lymphocytes / immunology*
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Killer Cells, Natural / immunology*
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Male
  • Mesothelioma / immunology*
  • Mesothelioma / mortality*
  • Mesothelioma / pathology
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Survival Rate
  • Tumor Microenvironment / immunology*